Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 11
2008 11
2009 17
2010 29
2011 38
2012 64
2013 62
2014 59
2015 72
2016 59
2017 64
2018 40
2019 44
2020 37
2021 35
2022 39
2023 27
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Results by year

Filters applied: . Clear all
Page 1
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. Sacco JJ, et al. Eur J Cancer. 2024 May;202:114009. doi: 10.1016/j.ejca.2024.114009. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38547774 Clinical Trial.
AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. ...
AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has s …
In ovo injection of AZD6244 suppresses feather follicle development by the inhibition of ERK and Wnt/beta-catenin pathways in goose embryos (Anser cygnoides).
Wang Y, Wang S, Mabrouk I, Zhou Y, Fu X, Song Y, Ma J, Hu X, Yang Z, Liu F, Hou J, Yu J, Sun Y. Wang Y, et al. Br Poult Sci. 2024 Feb 23:1-8. doi: 10.1080/00071668.2024.2309550. Online ahead of print. Br Poult Sci. 2024. PMID: 38393940
The 120 eggs were divided into four treatment groups, including an uninjected group (BLANK), a group injected with 100 l of cosolvent (CK), a group injected with 100 l of AZD6244 containing cosolvent in a dose of 5 mg/kg AZD6244 containing cosolvent (AZD5) and a gro …
The 120 eggs were divided into four treatment groups, including an uninjected group (BLANK), a group injected with 100 l of cosolvent (CK), …
Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X, Yu C, Zhou S, Zhang Y, Tian B, Bian Y, Wang W, Lin H, Wang LW. Zhang X, et al. Aging (Albany NY). 2024 Feb 1;16(3):2494-2516. doi: 10.18632/aging.205495. Epub 2024 Feb 1. Aging (Albany NY). 2024. PMID: 38305770 Free PMC article.
The high-risk group exhibited a greater response to immunotherapy and neoadjuvant chemotherapy than the low-risk group. Drug sensitivity analysis demonstrated lower IC50 for AZD6244 and PD.0332991 in high-risk groups and lower IC50 for cisplatin, ATRA, QS11, and vinorelbin …
The high-risk group exhibited a greater response to immunotherapy and neoadjuvant chemotherapy than the low-risk group. Drug sensitivity ana …
The miR-34b/MEK/ERK pathway is regulated by NR5A1 and promotes differentiation in primary bovine Sertoli cells.
Tao Q, Zhang L, Zhang Y, Liu M, Wang J, Zhang Q, Wu J, Wang A, Jin Y, Tang K. Tao Q, et al. Theriogenology. 2024 Feb;215:224-233. doi: 10.1016/j.theriogenology.2023.12.006. Epub 2023 Dec 9. Theriogenology. 2024. PMID: 38100994
Transfection of an miR-34b mimic into PSCs promoted cell differentiation, whereas transfection of an miR-34b inhibitor into PSCs delayed it. Pharmacological inhibition of MEK/ERK signaling by AZD6244 promoted PSCs differentiation. Mechanistically, miR-34b promoted PSCs dif …
Transfection of an miR-34b mimic into PSCs promoted cell differentiation, whereas transfection of an miR-34b inhibitor into PSCs delayed it. …
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
Song X, Wang L, Tang W, Yuan L, Liu Q, Li J, Fan D. Song X, et al. Arch Pharm Res. 2023 Dec;46(11-12):924-938. doi: 10.1007/s12272-023-01471-0. Epub 2023 Nov 30. Arch Pharm Res. 2023. PMID: 38032449
Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In our study, the results showed that selumetinib (AZD6244) synergistically inhibited the proliferation of NSCLC with gefitinib. ...
Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In o …
A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma.
Zhao Z, Shen X, Zhao S, Wang J, Tian Y, Wang X, Tang B. Zhao Z, et al. Aging (Albany NY). 2023 Nov 15;15(22):12927-12951. doi: 10.18632/aging.205211. Epub 2023 Nov 15. Aging (Albany NY). 2023. PMID: 37976136 Free PMC article.
Furthermore, high-risk DLBCL patients exhibited increased sensitivity to bortezomib, rapamycin, AZD6244, and BMS.536924, while low-risk DLBCL patients showed sensitivity to cisplatin and ABT.263. ...
Furthermore, high-risk DLBCL patients exhibited increased sensitivity to bortezomib, rapamycin, AZD6244, and BMS.536924, while low-ri …
618 results